Acute Lymphoblastic Leukemia study: CLIC-1901
Official title CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
ClinicalTrials.gov ID: NCT03765177
What this study is testing
What is CLIC-1901?
an investigational autologous anti‑CD19 CAR‑T cell therapy being studied for relapsed/refractory acute lymphoblastic leukemia (ALL). is designed to recognize and kill CD19‑positive cancer cells by redirecting the patient’s own T cells.
Also referred to as autologous anti‑CD19 CAR‑T cells.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn whether the CLIC-1901 CAR‑T cells are safe, can be given successfully, and work against the cancer.
- Who it's for
- People whose disease (acute lymphoblastic leukemia or non‑Hodgkin's lymphoma) has come back or not responded to standard treatments and whose cancer cells have the CD19 marker.
- What's involved
- Participants first receive two chemotherapy drugs (cyclophosphamide and fludarabine) to lower immune cells, then get a single intravenous infusion of their own T cells that have been engineered to target CD19.
- Time commitment
- The trial involves several clinic visits for the chemotherapy, the CAR‑T infusion, and follow‑up appointments over several months.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Participant must have relapsed or refractory CD19+ disease as defined by one of the following: a.
- All eligible participants must have documentation of CD19 tumour expression demonstrated in tissue biopsy, bone marrow or peripheral blood within the...
- Adequate organ function
- Participant age: 18 to 75 years.
- Provide written informed consent
You likely can't join if
- Isolated extra-medullary disease.
- Participants with concomitant genetic syndrome, such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known familial bone marrow...
- Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease.
- Prior treatment with any gene therapy product.
- Participants with polymerase chain reaction (PCR) positive hepatitis B, hepatitis C, or Human Immunodeficiency Virus (tested within 8 weeks of...
- Presence of active Graft Versus Host Disease requiring systemic therapy.
See the full eligibility criteria
- Participant must have relapsed or refractory CD19+ disease as defined by one of the following: a. Relapsed or refractory acute lymphoblastic leukemia or chronic lymphocytic leukemia as defined by one of the following...
- All eligible participants must have documentation of CD19 tumour expression demonstrated in tissue biopsy, bone marrow or peripheral blood within the 3 months prior to study screening.
- Adequate organ function
- Participant age: 18 to 75 years.
- Provide written informed consent
- Isolated extra-medullary disease.
- Participants with concomitant genetic syndrome, such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known familial bone marrow failure syndrome.
- Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease.
- Prior treatment with any gene therapy product.
- Participants with polymerase chain reaction (PCR) positive hepatitis B, hepatitis C, or Human Immunodeficiency Virus (tested within 8 weeks of screening), or any uncontrolled infection at screening.
- Presence of active Graft Versus Host Disease requiring systemic therapy.
- Participants who have undergone allogeneic SCT less than 6 months prior to CLIC-1901 cell infusion or who have undergone donor lymphocyte infusion less than 6 weeks prior to CLIC-1901 cell infusion.
- Active Central Nervous System (CNS) involvement by malignancy, defined by CNS-3 per National Comprehensive Cancer Network guidelines.
- History of anaphylaxis to gentamicin or its derivatives.
- Participant has received an investigational agent within the 30 days prior to enrolment visit.
- Pregnant or nursing women.
The study team makes the final eligibility decision.
Where it is enrolling
- Vancouver, British Columbia, Canada
- Ottawa, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Vancouver, British Columbia, Canada; Ottawa, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.